The China National Medical Products Administration (NMPA) has for Brukinsa (zanubrutinib).
The approvals were granted for two Supplemental Applications to covert conditional approval to regular approval, and two Supplemental New Drug Applications to treat Waldenstr枚m’s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The small molecule Bruton鈥檚 tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity.
In June 2021, the therapy received NMPA鈥檚 conditional approval to treat WM in adult patients, who have previously received a minimum of one therapy (R/R WM).
The NMPA also granted conditional approvals for Brukinsa in June 2020 to treat CLL/SLL and mantle cell lymphoma (MCL) in adult patients, who have previously received at least one therapy (R/R CLL/SLL and R/R MCL).
In April this year, the regulator converted these conditional approvals to regular approvals for R/R WM and R/R CLL/SLL.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBeiGene R&D global head Lai Wang said: 鈥淭hese approvals further support Brukinsa as the BTKi of choice in China for the treatment of B-cell malignancies such as CLL and WM.
鈥淲e look forward to bringing people living with CLL and WM a new first-line treatment option as we work to support the Healthy China initiative and reduce global health inequity.鈥�
The latest regulatory approvals from NMPA to treat CLL/SLL are supported by data from SEQUOIA, which was conducted in previously untreated CLL/SLL patients.
Brukinsa鈥檚 approvals to treat WM are based on data obtained from ASPEN, which is claimed to be the first and only global Phase III head-to-head clinical trial of BTK inhibitors in WM.
